Drug Trial Radar · NCT05776069
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Last checked: Nov 19, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Mar 16, 2023
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Vega Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Conditions
- Von Willebrand Diseases
Interventions
VGA039Drug
Single doses of VGA039
PlaceboOther
Single doses of Placebo
VGA039Drug
Multiple doses of VGA039
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]Time frame: From start of study drug administration until 15 or 8 weeks after IV or SC study drug administration, respectively
Locations
25 sites in 8 countries. Site status is shown where the registry gives one.
Orthopedic Institute for Children (UCLA)
Los Angeles, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
University of Colorado School of Medicine
Aurora, Colorado · Recruiting
Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory
Atlanta, Georgia · Recruiting
Science 37, Inc.
Morrisville, North Carolina · Recruiting
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
Washington Center for Bleeding Disorders
Seattle, Washington · Recruiting
Versiti Comprehensive Center for Bleeding Disorders
Milwaukee, Wisconsin · Recruiting
Royal Brisbane & Women's Hospital, Queensland Haemophilia Centre
Herston, Queenland, Australia · Recruiting
Medical University of Vienna
Vienna, State of Vienna, Austria · Completed
Centro de Hemoterapia e Hematologia do Rio de Janeiro HEMORIO
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Hemocentro Unicamp
Campinas, São Paulo, Brazil · Recruiting
Hospital das Clinicas - USP Endereco
São Paulo, São Paulo, Brazil · Recruiting
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada · Recruiting
Queens University
Kingston, Ontario, Canada · Recruiting
St. Michaels Hospital
Toronto, Ontario, Canada · Recruiting
K J Somaiya Super Speciality Hospital & Research Centre
Sion, Mumbai, India · Recruiting
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, South Africa · Recruiting
Imperial College Healthcare NHS Trust- Queen Charlotte's & Chelsea Hospital
London, United Kingdom · Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham, Edgbaston, United Kingdom · Recruiting
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, United Kingdom · Recruiting
Royal Free Hospital
London, London, United Kingdom · Recruiting
Royal London Hospital, Clinical Haematology Research
Whitechapel, London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.